Our approach is to target the first stress signal coming from the epithelium in the context of mucosal inflammatory disorders (MIDs). Doing so, we reinstate epithelial homeostasis by preventing inflammation, fibrosis and disruption of epithelial integrity. We also bring safety to patients as our approach is not immunosuppressive.
Our approach is to target the first stress signal coming from the epithelium in the context of mucosal inflammatory disorders (MIDs). Doing so, we reinstate epithelial homeostasis by preventing inflammation, fibrosis and disruption of epithelial integrity. We also bring safety to patients as our approach is not immunosuppressive.
Supported by a scientific team comprising the 3 scientific founders who are used to entrepreneurship and spent the past 15 years in academia (inserm and aphp) to identify and characterize the new target.
Our Team
Supported by a scientific team comprising the 3 scientific founders who are used to entrepreneurship and spent the past 15 years in academia (inserm and aphp) to identify and characterize the new target.